ReviewCurrent drug targets2026
Rheumatoid Arthritis Management: Emerging Drug Therapies and Innovations.
Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRheumatoid Arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent joint inflammation. Genetically predisposed conditions like Human Leukocyte Antigen DR1 (HLA-DR1) and Human Leukocyte Antigen DR4 (HLA-DR4), coupled with environmental insults like infection, smoking, diet, and stress, are etiological factors in immune dysregulation. It results in the overproduction of pro-inflammatory cytokines and autoantibodies, ultimately causing synovial inflammation and joint destruction. The objective of this review is to highlight the latest developments in RA management through new drug formulations, targeted biologics, and novel Drug Delivery Systems (DDS).
methodsA systematic literature search of scientific articles, registered trials, and published patents related to RA treatments was conducted. This review specifically focused on biologic Disease- Modifying Anti-Rheumatic Drugs (biologic DMARDs), small-molecule inhibitors, biomarker- directed personalized medicine, and DDS technologies.
resultsBiologic DMARDs, like Tumor Necrosis Factor (TNF) and interleukin inhibitors, have completely transformed the management of RA by targeting disease mechanisms. Small-molecule inhibitors became available with a similar efficacy to orally bioavailable forms. ADI has improved drug specificity, increased therapeutic efficacy, and decreased systemic toxicity. Biomarker- directed therapy has promise for improving treatment benefit. DISCUSSION: Current RA therapies highlight a shift toward biologics, personalized medicine, and advanced drug-delivery systems, enabling targeted action, reduced toxicity, and improved longterm disease management outcomes.
conclusionBiologic drugs, small-molecule inhibitors, and DDS technology are revolutionizing treatment for RA. These strategies increase efficacy, decrease side effects, and provide cost-effective, sustained therapy. The intersection of personalized medicine and advanced drug delivery is a future solution for enhancing patient outcomes and quality of life.
Indexed as
Identifiers
41832732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.